Leqembi (lekanemab) from Eisai and Biogen, which have recently obtained FDA approval, could potentially be registered in Russia within the current year. Elena Katunina, Head of the Department of Neurodegenerative Diseases at the Federal Center for Brain and Neurotechnologies of the Federal Medical and Biological Agency of Russia, has made the official announcement.
In an exciting press conference held on World Brain Day, it was revealed that this extraordinary drug is expected to receive its registration very soon, precisely within the upcoming autumn and winter seasons.
